JP2016210798A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016210798A5 JP2016210798A5 JP2016162881A JP2016162881A JP2016210798A5 JP 2016210798 A5 JP2016210798 A5 JP 2016210798A5 JP 2016162881 A JP2016162881 A JP 2016162881A JP 2016162881 A JP2016162881 A JP 2016162881A JP 2016210798 A5 JP2016210798 A5 JP 2016210798A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- excipient
- dopamine
- test
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 239000000546 pharmaceutical excipient Substances 0.000 claims 6
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 4
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 4
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims 4
- 208000004547 Hallucinations Diseases 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000022497 Cocaine-Related disease Diseases 0.000 claims 2
- 108010015720 Dopamine beta-Hydroxylase Proteins 0.000 claims 2
- 102100033156 Dopamine beta-hydroxylase Human genes 0.000 claims 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 claims 2
- 206010048010 Withdrawal syndrome Diseases 0.000 claims 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 230000003920 cognitive function Effects 0.000 claims 2
- 229960003638 dopamine Drugs 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000002532 enzyme inhibitor Substances 0.000 claims 2
- YZZVIKDAOTXDEB-JTQLQIEISA-N nepicastat Chemical compound NCC1=CNC(=S)N1[C@@H]1CC2=CC(F)=CC(F)=C2CC1 YZZVIKDAOTXDEB-JTQLQIEISA-N 0.000 claims 2
- 229950005868 nepicastat Drugs 0.000 claims 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 2
- 201000009032 substance abuse Diseases 0.000 claims 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims 1
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims 1
- HXTGXYRHXAGCFP-OAQYLSRUSA-N (r)-(2,3-dimethoxyphenyl)-[1-[2-(4-fluorophenyl)ethyl]piperidin-4-yl]methanol Chemical compound COC1=CC=CC([C@H](O)C2CCN(CCC=3C=CC(F)=CC=3)CC2)=C1OC HXTGXYRHXAGCFP-OAQYLSRUSA-N 0.000 claims 1
- 102000035038 5-HT1 receptors Human genes 0.000 claims 1
- 108091005478 5-HT1 receptors Proteins 0.000 claims 1
- 108050002825 5-Hydroxytryptamine 1A receptors Proteins 0.000 claims 1
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 claims 1
- 241001514645 Agonis Species 0.000 claims 1
- 208000007848 Alcoholism Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 206010013654 Drug abuse Diseases 0.000 claims 1
- 229940122459 Glutamate antagonist Drugs 0.000 claims 1
- 229940122439 Hydroxylase inhibitor Drugs 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 229940123257 Opioid receptor antagonist Drugs 0.000 claims 1
- 208000001431 Psychomotor Agitation Diseases 0.000 claims 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 claims 1
- 229940121991 Serotonin and norepinephrine reuptake inhibitor Drugs 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 206010044565 Tremor Diseases 0.000 claims 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 206010001584 alcohol abuse Diseases 0.000 claims 1
- 208000025746 alcohol use disease Diseases 0.000 claims 1
- 230000001773 anti-convulsant effect Effects 0.000 claims 1
- 230000001430 anti-depressive effect Effects 0.000 claims 1
- 230000000561 anti-psychotic effect Effects 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 229940005513 antidepressants Drugs 0.000 claims 1
- 229960003965 antiepileptics Drugs 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 230000002567 autonomic effect Effects 0.000 claims 1
- -1 catechol -O- methyl Chemical group 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 201000001272 cocaine abuse Diseases 0.000 claims 1
- 201000006145 cocaine dependence Diseases 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 235000019788 craving Nutrition 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims 1
- 239000000221 dopamine uptake inhibitor Substances 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 229940125532 enzyme inhibitor Drugs 0.000 claims 1
- 239000003825 glutamate receptor antagonist Substances 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000004050 mood stabilizer Substances 0.000 claims 1
- 229940127237 mood stabilizer Drugs 0.000 claims 1
- 230000008450 motivation Effects 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 claims 1
- 229960002748 norepinephrine Drugs 0.000 claims 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims 1
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 claims 1
- 239000004031 partial agonist Substances 0.000 claims 1
- 229940044551 receptor antagonist Drugs 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 claims 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 claims 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 claims 1
- 229940076279 serotonin Drugs 0.000 claims 1
- 239000003215 serotonin 5-HT2 receptor antagonist Substances 0.000 claims 1
- 239000003775 serotonin noradrenalin reuptake inhibitor Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000012034 trail making test Methods 0.000 claims 1
- 239000003558 transferase inhibitor Substances 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 claims 1
- 230000000007 visual effect Effects 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93532307P | 2007-08-06 | 2007-08-06 | |
| US60/935,323 | 2007-08-06 | ||
| US95655507P | 2007-08-17 | 2007-08-17 | |
| US60/956,555 | 2007-08-17 | ||
| US96059107P | 2007-10-04 | 2007-10-04 | |
| US60/960,591 | 2007-10-04 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014107381A Division JP2014148551A (ja) | 2007-08-06 | 2014-05-23 | 依存症治療方法 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018108758A Division JP2018154645A (ja) | 2007-08-06 | 2018-06-06 | 依存症治療方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016210798A JP2016210798A (ja) | 2016-12-15 |
| JP2016210798A5 true JP2016210798A5 (enExample) | 2017-06-15 |
Family
ID=40341713
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010520285A Pending JP2010535801A (ja) | 2007-08-06 | 2008-08-06 | 依存症治療方法 |
| JP2014107381A Pending JP2014148551A (ja) | 2007-08-06 | 2014-05-23 | 依存症治療方法 |
| JP2016162881A Pending JP2016210798A (ja) | 2007-08-06 | 2016-08-23 | 依存症治療方法 |
| JP2018108758A Pending JP2018154645A (ja) | 2007-08-06 | 2018-06-06 | 依存症治療方法 |
| JP2020081105A Pending JP2020114883A (ja) | 2007-08-06 | 2020-05-01 | 依存症治療方法 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010520285A Pending JP2010535801A (ja) | 2007-08-06 | 2008-08-06 | 依存症治療方法 |
| JP2014107381A Pending JP2014148551A (ja) | 2007-08-06 | 2014-05-23 | 依存症治療方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018108758A Pending JP2018154645A (ja) | 2007-08-06 | 2018-06-06 | 依存症治療方法 |
| JP2020081105A Pending JP2020114883A (ja) | 2007-08-06 | 2020-05-01 | 依存症治療方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US20090041800A1 (enExample) |
| EP (2) | EP3251670A1 (enExample) |
| JP (5) | JP2010535801A (enExample) |
| CN (2) | CN106983747A (enExample) |
| AU (1) | AU2008283903B2 (enExample) |
| BR (1) | BRPI0815089A2 (enExample) |
| CA (1) | CA2695372C (enExample) |
| CO (1) | CO6260015A2 (enExample) |
| ES (1) | ES2638190T3 (enExample) |
| IL (1) | IL257418A (enExample) |
| MX (4) | MX2010001390A (enExample) |
| NZ (1) | NZ583192A (enExample) |
| PH (1) | PH12015502210A1 (enExample) |
| RU (1) | RU2491067C2 (enExample) |
| SG (2) | SG10201705968RA (enExample) |
| WO (1) | WO2009021055A1 (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3251670A1 (en) | 2007-08-06 | 2017-12-06 | Biotie Therapies, Inc. | Methods for treating dependence |
| WO2010124089A2 (en) * | 2009-04-22 | 2010-10-28 | Synosia Therapeutics, Inc. | Methods for treating dependence |
| US9804149B2 (en) * | 2012-10-10 | 2017-10-31 | Bio-Rad Laboratories, Inc. | Patient-based results display |
| CA3042642A1 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| US10172797B2 (en) | 2013-12-17 | 2019-01-08 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| CA2875384A1 (en) | 2013-12-20 | 2015-06-20 | AntiOP, Inc. | Intranasal naloxone compositions and methods of making and using same |
| CA2955229C (en) | 2014-07-17 | 2020-03-10 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
| AU2015336065A1 (en) | 2014-10-20 | 2017-05-04 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| US20170235908A1 (en) * | 2015-11-15 | 2017-08-17 | Oriah Behaviorial Health, Inc. | Systems and Methods for Managing and Treating Substance Abuse Addiction |
| EP3668490A4 (en) * | 2017-08-20 | 2021-06-09 | Formulex Pharma Innovations Ltd. | Dry powder compositions for intranasal delivery |
| US11844859B2 (en) | 2017-08-20 | 2023-12-19 | Nasus Pharma Ltd. | Dry powder compositions for intranasal delivery |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| CN108066355A (zh) * | 2017-12-28 | 2018-05-25 | 宁夏恩多芬科技有限公司 | Nitrous Oxide作为治疗神经官能症的用途 |
| FR3093419B1 (fr) * | 2019-03-08 | 2021-06-18 | Univ Grenoble Alpes | Composition et procédé associé de mesure de l’observance thérapeutique |
| US12377112B2 (en) | 2019-04-17 | 2025-08-05 | Compass Pathfinder Limited | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation |
| KR20220082092A (ko) * | 2019-11-07 | 2022-06-16 | 스몰 파마 엘티디 | 화합물 |
| US11806320B2 (en) * | 2020-02-19 | 2023-11-07 | Endo Ventures Limited | Isoproterenol compositions and methods |
| US12240813B2 (en) | 2020-05-19 | 2025-03-04 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| AU2021328259A1 (en) * | 2020-08-17 | 2023-02-23 | The Research Foundation For Mental Hygiene, Inc. | Use of neuromelanin-sensitive MRI as a biomarker of dopamine function |
| CN116391128B (zh) * | 2020-10-24 | 2025-11-21 | 巴塞尔大学医院 | 人血浆中麦角酸二乙基酰胺（lsd）和2,3-二氢-3-羟基-2-氧代麦角二乙胺（o-h-lsd）的定量方法 |
| US12029718B2 (en) | 2021-11-09 | 2024-07-09 | Cct Sciences, Llc | Process for production of essentially pure delta-9-tetrahydrocannabinol |
| CN112690771B (zh) * | 2020-12-09 | 2022-05-24 | 华南理工大学 | 一种利用线性回归模型的人脸视频心率检测方法 |
| CN117098496A (zh) | 2021-03-11 | 2023-11-21 | 人类生物科学股份有限公司 | 用于协调包括生物标志物的成像数据集的系统、装置和方法 |
| CN113017632B (zh) * | 2021-03-17 | 2022-11-11 | 陈思 | 一种智慧校园心理咨询辅助方法及系统 |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| US20260062388A1 (en) | 2022-09-16 | 2026-03-05 | Jiangsu Yahong Meditech Co., Ltd. | Polymorphic form of nepicastat acid addition salt, preparation method therefor and use thereof |
| WO2024178082A2 (en) * | 2023-02-22 | 2024-08-29 | Freedom Biosciences, Inc. | Composition of opioid receptor modulator and mdma for use thereof |
| CN120754106B (zh) * | 2025-09-02 | 2025-12-09 | 合肥工业大学 | 化合物sch23390在制备治疗铅中毒药物中的应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989003211A1 (en) * | 1987-10-07 | 1989-04-20 | Matrix Technologies, Incorporated | Treatment of cocaine addiction |
| US5593367A (en) * | 1995-08-18 | 1997-01-14 | Deere & Company | Switchable ignition and starter control system |
| JP2000506832A (ja) * | 1996-02-23 | 2000-06-06 | ファーム―エコ ラボラトリーズ，インコーポレイテッド | 選択的なｄ１ドーパミンレセプターアゴニスト及び部分的アゴニスト／アンタゴニスト |
| US5958896A (en) * | 1997-08-08 | 1999-09-28 | The Mclean Hospital | Cytidine-containing and cytosine-containing compounds as treatments for stimulant exposure |
| US6541520B1 (en) * | 1998-08-05 | 2003-04-01 | Brookhaven Science Associates | Treatment of addiction and addiction-related behavior |
| KR100712570B1 (ko) * | 2001-01-17 | 2007-05-02 | 하이디엄, 인크. | 알콜 의존성 치료약의 제조에서 플루마제닐의 용도 |
| US20030040015A1 (en) * | 2001-03-07 | 2003-02-27 | Kwang-Soo Kim | Methods and reagents for identifying compounds and mutations that modulate dopamine beta-hydroxylase activity |
| SE0104388D0 (sv) * | 2001-12-27 | 2001-12-27 | Pharmacia Ab | New formulation and use and manufacture thereof |
| AU2004216360B2 (en) * | 2003-02-27 | 2009-09-17 | Eisai R & D Management Co., Ltd. | Pharmaceutical composition for treatment of drug dependence |
| RU2252756C1 (ru) * | 2003-12-23 | 2005-05-27 | Хохлов Александр Петрович | Препарат против алкоголизма и наркомании, способ получения такого препарата |
| WO2008115706A1 (en) * | 2007-03-16 | 2008-09-25 | Emory University | Methods and compositions for treatment of drug addiction |
| SG183069A1 (en) * | 2007-07-23 | 2012-08-30 | Synosia Therapeutics | Treatment of post-traumatic stress disorder |
| AU2008279169A1 (en) * | 2007-07-23 | 2009-01-29 | Biotie Therapies, Inc | 4-hydroxy-4-methyl-piperidine-1-carboxylic acid (4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide for the treatment of post-traumatic stress disorder |
| WO2009015244A1 (en) * | 2007-07-23 | 2009-01-29 | Synosia Therapeutics | Rufinamide for the treatment of post-traumatic stress disorder |
| EP3251670A1 (en) | 2007-08-06 | 2017-12-06 | Biotie Therapies, Inc. | Methods for treating dependence |
| US20100243466A1 (en) | 2007-11-26 | 2010-09-30 | Bridgestone Corporation | Copper-zinc alloy electroplating bath and plating method using the copper-zinc alloy electroplating bath |
-
2008
- 2008-08-06 EP EP17165804.0A patent/EP3251670A1/en not_active Withdrawn
- 2008-08-06 JP JP2010520285A patent/JP2010535801A/ja active Pending
- 2008-08-06 CN CN201611204491.7A patent/CN106983747A/zh active Pending
- 2008-08-06 BR BRPI0815089-3A2A patent/BRPI0815089A2/pt not_active IP Right Cessation
- 2008-08-06 MX MX2010001390A patent/MX2010001390A/es not_active Application Discontinuation
- 2008-08-06 EP EP08797300.4A patent/EP2182804B1/en not_active Not-in-force
- 2008-08-06 MX MX2015009454A patent/MX357542B/es unknown
- 2008-08-06 SG SG10201705968RA patent/SG10201705968RA/en unknown
- 2008-08-06 CA CA2695372A patent/CA2695372C/en not_active Expired - Fee Related
- 2008-08-06 AU AU2008283903A patent/AU2008283903B2/en not_active Ceased
- 2008-08-06 US US12/187,166 patent/US20090041800A1/en not_active Abandoned
- 2008-08-06 CN CN200880109939A patent/CN101815438A/zh active Pending
- 2008-08-06 SG SG2012058210A patent/SG183696A1/en unknown
- 2008-08-06 NZ NZ583192A patent/NZ583192A/en not_active IP Right Cessation
- 2008-08-06 MX MX2018008628A patent/MX391921B/es unknown
- 2008-08-06 RU RU2010108249/15A patent/RU2491067C2/ru active
- 2008-08-06 ES ES08797300.4T patent/ES2638190T3/es active Active
- 2008-08-06 WO PCT/US2008/072357 patent/WO2009021055A1/en not_active Ceased
-
2010
- 2010-02-04 MX MX2022001510A patent/MX2022001510A/es unknown
- 2010-02-26 CO CO10023191A patent/CO6260015A2/es not_active Application Discontinuation
-
2013
- 2013-12-06 US US14/099,882 patent/US10561638B2/en not_active Expired - Fee Related
-
2014
- 2014-05-23 JP JP2014107381A patent/JP2014148551A/ja active Pending
-
2015
- 2015-09-22 PH PH12015502210A patent/PH12015502210A1/en unknown
-
2016
- 2016-08-23 JP JP2016162881A patent/JP2016210798A/ja active Pending
-
2018
- 2018-02-08 IL IL257418A patent/IL257418A/en unknown
- 2018-06-06 JP JP2018108758A patent/JP2018154645A/ja active Pending
-
2020
- 2020-01-07 US US16/736,609 patent/US20200383951A1/en not_active Abandoned
- 2020-05-01 JP JP2020081105A patent/JP2020114883A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016210798A5 (enExample) | ||
| Henter et al. | Novel glutamatergic modulators for the treatment of mood disorders: current status | |
| Marcinkowska et al. | Management of dementia-related psychosis, agitation and aggression: a review of the pharmacology and clinical effects of potential drug candidates | |
| Cardinali et al. | Melatonin and its analogs in insomnia and depression | |
| Kulkarni et al. | On the mechanism of antidepressant-like action of berberine chloride | |
| Goldenberg | Medical management of Parkinson’s disease | |
| Nemeroff et al. | Duloxetine for the treatment of major depressive disorder | |
| Bellingham et al. | Duloxetine: a review of its pharmacology and use in chronic pain management | |
| JP2010535801A5 (enExample) | ||
| US11826321B2 (en) | Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions | |
| US12521374B1 (en) | Combination therapy for a dopamine agonist | |
| JP2021080288A (ja) | 吃音を治療するための融合ベンズアゼピン | |
| Kirwin et al. | Duloxetine: A dual serotonin‐norepinephrine reuptake inhibitor for treatment of major depressive disorder | |
| JP2013536837A (ja) | コカイン嗜癖の治療 | |
| Celikyurt et al. | Serotonin noradrenaline reuptake inhibitors (SNRIs) | |
| Cai et al. | Potential anti-depressive treatment maneuvers from bench to bedside | |
| Majid et al. | Therapeutics of narcolepsy | |
| BESHIR et al. | Pharmaceutical sleep medications and medications that affect sleep | |
| TWI922961B (zh) | 用於治療抑鬱症之組合物及方法 | |
| AU2024204318A1 (en) | Treatment of Post-Traumatic Syndrome Disorder | |
| Kominek et al. | Coanalgesic | |
| Soroka et al. | Ketamine in affective disorders–expectations and limitations | |
| EP4618981A1 (en) | Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use | |
| HK40116800A (zh) | 用於治疗抑郁的组合物和方法 | |
| AU2012307535A1 (en) | Combinations comprising a S1P receptor modulator |